Table 3 Factors associated with sustained viral response to interferon-alpha therapy
Total No. | Non-SVR† No. (%) | SVR† No. (%) | P value | |
|---|---|---|---|---|
Patient Number | 200 | 136(68.0) | 64(32.0) | |
Gender | NS‡ | |||
Male | 103 | 69(70.0) | 34(33.0) | |
Female | 97 | 67(69.1) | 30(30.9) | |
Age (year) | 47.6 ± 10.0 | 44.2 ± 13.5 | NS | |
History of transfusion | NS | |||
No | 141 | 97(68.8) | 44(31.2) | |
Yes | 59 | 39(66.1) | 20(33.9) | |
Liver histopathology | ||||
Total score of necroinflammatory activity | 4.10 ± 2.59 | 4.21 ± 2.31 | NS | |
Fibrosis score | <0.01 | |||
F3–4 | 70 | 57(81.4) | 13(18.6) | |
F0–2 | 130 | 79(60.8) | 51(39.2) | |
Pretreatment ALT value (IU/L) | 87.8 ± 86.5 | 143.5 ± 153.5 | <0.01 | |
Pretreatment serum level of HCV RNA§ | 6.17 ± 0.61 | 5.62 ± 0.56 | <0.0001 | |
HCV genotype | ||||
1b | 80 | 63(78.8) | 17(21.3) | <0.01 |
Non-1b | 120 | 73(60.8) | 47(39.2) | |
Interferon preparation | NS | |||
Recombinant IFN-α-2a | 37 | 29(78.4) | 8(21.6) | |
Recombinant IFN-α-2b | 95 | 62(65.3) | 33(34.7) | |
Lymphoblastoid IFN-α-n1 | 68 | 45(66.2) | 23(33.8) | |
Interferon regimen | <0.05 | |||
3-MU group¶ | 76 | 58(76.3) | 18(23.7) | |
6-MU group¶ | 124 | 78(62.1) | 46(37.1) | |